{"id":{"repo_id":"buffalo","oai_identifier":"oai:ubir.buffalo.edu:10477/86843"},"canonical_url":"https://search.dev.ndltd.org/etd/buffalo/oai:ubir.buffalo.edu:10477/86843","repository":{"repo_id":"buffalo","name":"Buffalo","base_url":"https://ubir.buffalo.edu/oai/request"},"display":{"title":"Developing a Novel Liposomal Adjuvant for Malaria Transmission-Blocking Vaccines","abstract":"Ph.D.","abstract_html":"Ph.D.","abstract_has_math":false,"creators":["Huang, Wei-Chiao; 0000-0001-6239-3266"],"institution":"State University of New York at Buffalo","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Lovell, Jonathan","Biomedical Engineering"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025-02-25T23:23:21Z","date_published":"2025-02-25T23:23:21Z","updated_at":"2026-07-27T19:05:37Z","subjects":["biomedical engineering","biology"],"languages":["eng"],"rights":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10477/86843","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Lovell, Jonathan","Biomedical Engineering"]},{"key":"dc:creator","label":"Author","values":["Huang, Wei-Chiao; 0000-0001-6239-3266"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2025-02-25T23:23:21Z","2020","2020-08-06 09:57:43"]},{"key":"dc:publisher","label":"Institution","values":["State University of New York at Buffalo"]},{"key":"dc:type","label":"Dc Type","values":["Text","Dissertation"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["biomedical engineering","biology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/10477/86843"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Ph.D.","Malaria is one of the most severe public health problems, and is caused by Plasmodium parasites. Currently, there is no effective vaccine considered effective enough to lead to malaria eradication. The concept of transmission-blocking vaccines (TBV) is to prevent the spreading of parasites from person to mosquito vector. The ability of TBV to break the cycle of malarial parasite transmission between human to mosquito could be a potent approach for malaria eradication. However, the lack of progress in TBV development is due to the absence of a suitable vaccine which can provide strong immune response with minimal side effects and many TBV antigens suffer from poor immunogenicity. Liposomal adjuvants are important systems in vaccine developments, and the lipid monophosphoryl lipid A (MPLA) has been proven in licensed vaccines. Previous studies have shown that liposomes containing cobalt porphyrin phospholipid (CoPoP) facilitate particleization of polyhistidine tag (his-tagged) peptides without covalent conjugation or additional functional group modification. The main goal of the research in this thesis is to evaluate the impact of antigen particleization with CoPoP liposomes for TBV development. At the beginning of this thesis, a general introduction on malaria and the concept of transmission-blocking vaccines is introduced, and the application of different types of adjuvants used for TBV are discussed...Overall, the studies in this PhD thesis have demonstrated the potential for developing an effective vaccine against transmission blocking stage for Plasmodium falciparum, as well as the potential for combining different stage of malaria antigen for vaccine development.","**To request an accessible version of the file(s) associated with this item, contact library@buffalo.edu. Please include the item's persistent URL [http://hdl.handle.net/. . .] in your request.**"]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Developing a Novel Liposomal Adjuvant for Malaria Transmission-Blocking Vaccines"]}]}],"canonical_facts":{"dc:contributor":["Lovell, Jonathan","Biomedical Engineering"],"dc:creator":["Huang, Wei-Chiao; 0000-0001-6239-3266"],"dc:date":["2025-02-25T23:23:21Z","2020","2020-08-06 09:57:43"],"dc:description":["Ph.D.","Malaria is one of the most severe public health problems, and is caused by Plasmodium parasites. Currently, there is no effective vaccine considered effective enough to lead to malaria eradication. The concept of transmission-blocking vaccines (TBV) is to prevent the spreading of parasites from person to mosquito vector. The ability of TBV to break the cycle of malarial parasite transmission between human to mosquito could be a potent approach for malaria eradication. However, the lack of progress in TBV development is due to the absence of a suitable vaccine which can provide strong immune response with minimal side effects and many TBV antigens suffer from poor immunogenicity. Liposomal adjuvants are important systems in vaccine developments, and the lipid monophosphoryl lipid A (MPLA) has been proven in licensed vaccines. Previous studies have shown that liposomes containing cobalt porphyrin phospholipid (CoPoP) facilitate particleization of polyhistidine tag (his-tagged) peptides without covalent conjugation or additional functional group modification. The main goal of the research in this thesis is to evaluate the impact of antigen particleization with CoPoP liposomes for TBV development. At the beginning of this thesis, a general introduction on malaria and the concept of transmission-blocking vaccines is introduced, and the application of different types of adjuvants used for TBV are discussed...Overall, the studies in this PhD thesis have demonstrated the potential for developing an effective vaccine against transmission blocking stage for Plasmodium falciparum, as well as the potential for combining different stage of malaria antigen for vaccine development.","**To request an accessible version of the file(s) associated with this item, contact library@buffalo.edu. Please include the item's persistent URL [http://hdl.handle.net/. . .] in your request.**"],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/10477/86843"],"dc:language":["eng"],"dc:publisher":["State University of New York at Buffalo"],"dc:rights":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."],"dc:subject":["biomedical engineering","biology"],"dc:title":["Developing a Novel Liposomal Adjuvant for Malaria Transmission-Blocking Vaccines"],"dc:type":["Text","Dissertation"]},"updated_at":"2026-07-27T19:05:37Z"}